Clinical Development of COVID-19 Therapeutics
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 75N93023C00052-P00001-9999-1
Grant search
Key facts
Disease
COVID-19Start & end year
20232026Known Financial Commitments (USD)
$1,300,776Funder
National Institutes of Health (NIH)Principal Investigator
STANLEY WANGResearch Location
United States of AmericaLead Research Institution
ALIGOS THERAPEUTICS, INC.Research Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Pre-clinical studies
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Clinical Trial, Phase I
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Other
Occupations of Interest
Unspecified
Abstract
To support the advanced development of candidate therapeutics for a virus covered under the Antiviral Program for Pandemics. The supported research and development activities will progress the therapeutic product development and may include lead optimization, candidate selection, preclinical and IND enabling studies, Chemistry, Manufacturing, and Controls (CMC), IND submission, clinical safety and efficacy assessment. Efforts include a Phase I clinical trial in renal and hepatic impaired patients.